Dimethylformamide → HCID 59592904, compound

HRID 2262191Notes

Reaction equation

HRID 2262191 reaction equation
Br[CH2:2][C:3]1[S:11][C:10]2[C:9]([N:12]3[CH2:17][CH2:16][O:15][CH2:14][CH2:13]3)=[N:8][C:7](Cl)=[N:6][C:5]=2[CH:4]=1.Cl.[CH3:20][NH:21][CH3:22].C([O-])([O-])=O.[K+].[K+].C[N:30]([CH:32]=O)C>>[NH:30]1[C:32]2[C:10](=[C:5]([C:7]3[N:8]=[C:9]([N:12]4[CH2:17][CH2:16][O:15][CH2:14][CH2:13]4)[C:10]4[S:11][C:3]([CH2:2][N:21]([CH3:22])[CH3:20])=[CH:4][C:5]=4[N:6]=3)[CH:4]=[CH:3][CH:2]=2)[CH:9]=[N:8]1

Participants

5

Reactant 4

HCID 6228DimethylformamideHCID 10473Dimethylamine, hydrochlorideHCID 11430Potassium CarbonateHCID 461807264-(6-(Bromomethyl)-2-chlorothieno[3,2-d]pyrimidin-4-yl)morpholine

Product 1

HCID 59592904HCID 59592904, compound

Procedure

To a solution of 6-(bromomethyl)-2-chloro-4-morpholinothieno[3,2-d]pyrimidine 30 from Example 9 (90 mg, 0.3 mmol) in DMF (3 mL) was added dimethylamine hydrochloride (21 mg, 0.3 mmol) and K2CO3 (90 mg, 0.6 mmol). The resulting solution stirred at room temperature overnight then was concentrated in vacuo. The residue was diluted with water and filtered. The crude product was utilized in a Suzuki coupling using General Procedure A with 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole 7 to provide 304 after reverse phase HPLC purification (34 mg). MS (Q1) 395 (M)+

Workup

  1. concentrationthen was concentrated in vacuo
  2. additionThe residue was diluted with water
  3. filtrationfiltered

Sources & evidence

ORD record
ord-31fb831ef5ae41278cd76ccfb8548e99
Source dataset
uspto-grants-2010_12
Patent number
US07846929B2

Reaction notes

Loading…